Brief: Vicore Obtains SARS Coronavirus Patent For C21 In US

Vicore Pharma Holding AB

22/09/2021 07:05

Sept 22 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE OBTAINS SARS CORONAVIRUS PATENT FOR C21 IN THE USA
    * AN ONGOING INTERNATIONAL PIVOTAL PHASE 3 STUDY (ATTRACT-3)
INVOLVING AROUND 600 COVID-19 PATIENTS IS EXPECTED TO DELIVER
TOP-LINE DATA IN H1 2022
    * U.S. PATENT AND TRADEMARK OFFICE (USPTO) HAS GRANTED
PATENT
NUMBER US11,123,329 COVERING USE OF C21 TO TREAT INFECTIONS
CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS
(COV), INCLUDING SARS-COV-2
    * A MAJOR CLINICAL IMPACT OF C21 ON RESPIRATORY FUNCTION IN
COVID-19 WAS DOCUMENTED IN A RECENT PHASE 2 TRIAL SHOWING THAT
C21 REDUCED NEED FOR SUPPLEMENTAL OXYGEN IN HOSPITALIZED
PATIENTS BY 90%

Source text for Eikon:  ID:nWkr25dlmm 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))